Non-invasive FibroScan to gauge fibrosis and steatosis debuts

Non-invasive FibroScan to gauge fibrosis and steatosis debuts

Monday, December 17, 2018


NCH is now offering FibroScan® (liver elastography), a non-invasive diagnostic tool used to assess fibrosis and steatosis in chronic liver disease. The advanced ultrasound technology enables physicians to measure the stiffness of a patient’s liver. The harder the liver is, the more significant the fibrosis. FibroScan is a painless alternative to a liver biopsy. Physicians are able to avoid risks associated with a liver biopsy.

FibroScan emits a pulse through a small transducer on the end of an ultrasound probe placed on the skin’s surface. It measures the liver’s condition through sound waves. The data is analyzed by a computer that displays a two-dimensional picture of the liver.

FibroScan is used in the clinical management of patients with liver disease, including:

  • Cirrhosis
  • Alcoholic liver disease
  • Non-alcoholic steatohepatitis
  • Hepatitis B
  • Hepatitis C
  • Autoimmune hepatitis
  • Genetic diseases (e.g., hemochromatosis, Wilson’s disease)

Furthermore, FibroScan may improve detection of cirrhosis and fibrosis because of the ability to repeatedly test without the adverse effects of a liver biopsy. The procedure typically takes 15 minutes or less. Results will be reviewed by our medical director and forwarded to the referring physician.

Physicians may order liver elastography electronically or may fax the order to 847-618-3709. Please encourage patients to call NCH Central Scheduling at 847-618-3700 to schedule an appointment.

See a list of ICD-10 codes approved for FibroScan.

Print

Name:
Email:
Subject:
Message:
x